Since 1998 pulmonary hypertension has been clinically classified into five well-defined, distinct categories. A definitive diagnosis of pulmonary hypertension requires the invasive confirmation of an elevated mean pulmonary artery pressure of 25 mm Hg or above during a right heart catheterization. From a hemodynamic point of view, pulmonary hypertension is classified into precapillary and postcapillary pulmonary hypertension on the basis of a pulmonary artery wedge pressure threshold value of 15 mm Hg. Pulmonary vascular resistance is better characterized by multi-point pressure/flow measurements than by single-point determination. Multi-point pulmonary vascular resistance calculation could be useful for early disease identification as well as for treatment response assessment. Occlusion analysis of the pulmonary artery pressure decay curve after balloon inflation at the tip of the pulmonary artery catheter permits locating the site of predominantly increased resistance and could be useful in differentiating proximal from distal vasculopathy, especially in chronic thromboembolic pulmonary hypertension. The pulsatile hydraulic load of the pulmonary circulation can be better appreciated by pulmonary vascular impedance or via the resistance-compliance relationship than by means of pulmonary vascular resistance. Determination of right ventriculo-arterial coupling permits assessing the impact of an elevated afterload on right ventricular function, which ultimately determines the symptoms and prognosis of patients with pulmonary hypertension. The clinical utility of combining different invasive hemodynamic approaches is still uncertain and remains to be determined.

Keywords:
Right heart catheterization, Pulmonary vascular resistance, Partitioning of pulmonary vascular resistance, Pulmonary vascular impedance, Right ventriculo-arterial coupling
1.
Hoeper MM, Bogaard HJ, Condliffe R, Franzt R, Khanna D, Kurzyna M, et al: Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol 2013; 62(suppl):D42–D50.
2.
Galiè N, Humbert M, Vachiéry JL, Gibbs S, Lang I, Torbicki A, et al: 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS) endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society of Heart and Lung Trans-plantation (ISHLT). Eur Heart J 2016; 37: 67–119.
3.
Hatano S, Strasser T: Primary Pulmonary Hypertension, Report on a WHO Meeting. October 15–17, 1973. Geneva, World Health Organization, 1975.
4.
Simonneau G, Gatzoulis MA, Adatia I, Celer-majer D, Denton C, Ghofrani A, et al: Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013; 62(suppl): D34–D41.
5.
Vachiéry JL, Adir Y, Barberà JA, Champion H, Coghlan JR, Cottin V, et al: Pulmonary ypertension due to left heart diseases. J Am Coll Cardiol 2013; 62(suppl):D100– D108.
6.
Rich JD, Rich S: Clinical diagnosis of pulmonary hypertension. Circulation 2014; 130: 1820–1830.
7.
Seeger W, Adir Y, Barberà JA, Champion H, Coghlan FG, Cottin V, et al: Pulmonary hypertension in chronic lung diseases. J Am Coll Cardiol 2013; 62(suppl):D109–D116.
8.
Lang IM, Madani M: Update on chronic thromboembolic pulmonary hypertension. Circulation 2014; 130: 508–518.
9.
McGoon MD, Benza RL, Escribano-Subias P, Jiang X, Miller DP, Peacock AJ, et al: Pulmonary arterial hypertension: epidemiology and registries. J Am Coll Cardiol 2013; 62(suppl): D51–D59.
10.
Ling Y, Johnson MK, Kiely DG, Condliffe R, Elliot CA, Gibbs JS, et al: Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland. Am J Respir Crit Care Med 2012; 186: 790–796.
11.
Kovacs G, Berghold A, Scheidl S, Olschewski H: Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review. Eur Respir J 2009; 34: 888–894.
12.
Lau EMT, Godinas L, Sitbon O, Montani D, Savale L, Jaïs X, et al: Resting pulmonary artery pressure of 21–24 mm Hg predicts abnormal exercise haemodynamics. Eur Respir J 2016; 47: 1436–1444.
13.
Barst RJ, McGoon M, Torbicki A, Sitbon O, Krowka MJ, Olschewski H, et al: Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43(suppl S):40S–47S.
14.
Hervé P, Lau EM, Sitbon O, Savale L, Montani D, Godinas L, et al: Criteria for diagnosis of exercise pulmonary hypertension. Eur Respir J 2015; 46: 728–737.
15.
Halpern SD, Taichman DB: Misclassification of pulmonary hypertension due to reliance on pulmonary capillary wedge pressure rather than left ventricular end-diastolic pressure. Chest 2009; 136: 37–43.
16.
Paulus WJ, Tschöpe C, Sanderson JE, Rusconi C, Flachskampf F, Rademakers FE, et al: How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007; 28: 2539–2550.
17.
LeVarge BL, Pomerantsev E, Channick RN: Reliance on end-expiratory wedge pressure leads to misclassification of pulmonary hypertension. Eur Respir J 2014; 44: 425–434.
18.
Naeije R: Pulmonary vascular resistance. A meaningless variable? Intensive Care Med 2003; 29: 526–529.
19.
Leeman M, Lejeune P, Closset J, Vachiéry JL, Mélot C, Naeije R: Nature of pulmonary hypertension in canine oleic acid pulmonary edema. J Appl Physiol (1985) 1990; 69: 293–298.
20.
Pagnamenta A, Fesler P, Vandinivit A, Brimioulle S, Naeije R: Pulmonary vascular effects of dobutamine in experimental pulmonary hypertension. Crit Care Med 2003; 31: 1140–1146.
21.
Castelain V, Chemla D, Humbert M, Sitbon O, Simonneau G, Lecarpentier Y, et al: Pulmonary artery pressure-flow relations after prostacyclin in primary pulmonary hypertension. Am J Respir Crit Care Med 2002; 165: 338–340.
22.
Provencher S, Hervé P, Sitbon O, Humbert M, Simonneau G, Chelma D: Changes in exercise haemodynamics during treatment in pulmonary arterial hypertension. Eur Respir J 2008; 32: 393–398.
23.
Lau EMT, Vanderpool RR, Choudhary P, Simmons LR, Corte TJ, Argiento P, et al: Dobutamine stress echocardiography for the assessment of pressure-flow relationships of the pulmonary circulation. Chest 2014; 146: 959–966.
24.
Ganter CG, Jakob M, Takala J: Pulmonary capillary pressure. Minerva Anestesiol 2006; 72: 21–36.
25.
Souza R, Amato MB, Demarzo SE, Deheinzelin D, Barbas CS, Schettino GP, Carvalho CR: Pulmonary capillary pressure in pulmonary hypertension. Crit Care 2005; 9:R132–R138.
26.
Fesler P, Pagnamenta A, Vachiéry JL, Brimi-oulle S, Abdel Kafi S, Boonstra A, et al: Single arterial occlusion to locate resistance in patients with pulmonary hypertension. Eur Respir J 2003; 21: 31–36.
27.
Kim NHS, Fesler P, Channick RN, Knowlton KU, Ben-Yehuda O, Lee SH, et al: Preoperative partitioning of pulmonary vascular resistance correlates with early outcome after thromboendarterectomy for chronic thromboembolic pulmonary hypertension. Circulation 2004; 109: 18–22.
28.
Toshner M, Suntharalingam J, Fesler P, Soon E, Sheares KK, Jenkins D, et al: Occlusion pressure analysis role in partitioning of pulmonary vascular resistance in CTEPH. Eur Respir J 2012; 40: 612–617.
29.
Gidwani UK, Mohanty B, Chatterjee K: The pulmonary artery catheter: a critical reappraisal. Cardiol Clin 2013; 31: 545–565.
30.
Rosenkranz S, Preston IR: Right heart catheterisation: best practice and pitfalls in pulmonary hypertension. Eur Respir Rev 2015; 24: 642–652.
31.
Milnor WR: Hemodynamics, ed 2. Baltimore, Williams & Wilkins, 1989.
32.
Grant BJ, Lieber BB: Clinical significance of pulmonary arterial input impedance. Eur Respir J 1996; 9: 2196–2199.
33.
Vonk-Noordegraf A, Haddad F, Chin KM, Forfia PR, Kawut SM, Lumens J, et al: Right heart adaptation to pulmonary arterial hypertension: physiology and pathobiology. J Am Coll Cardiol 2013; 62(suppl):D22–D33.
34.
Tedford RY: Determinants of right ventricular afterload (2013 Grover Conference series). Pulm Circ 2014; 4: 211–219.
35.
Naeije R: Pulmonary circulation; in Grippi MA, et al (eds): Fishman’s Pulmonary Diseases and Disorders, ed 5. McGraw Hill Medical, 2015, chapter 13.
36.
Pagnamenta A, Vanderpool R, Brimioulle S, Naeije R: Proximal pulmonary arterial obstruction decreases the time constant of the pulmonary circulation and increases right ventricular afterload. J Appl Physiol (1985) 2013; 114: 1586–1592.
37.
Stergiopulos N, Meister JJ, Westerhof N: Evaluation of methods for estimation of total arterial compliance. Am J Physiol 1995; 268:H1540–H1548.
38.
Lankhaar JW, Westerhof N, Faes TJ, Gan CT, Marques KM, Boonstra A, et al: Pulmonary vascular resistance and compliance stay inversely related during treatment of pulmonary hypertension. Eur Heart J 2008; 29: 1688–1695.
39.
Saouti N, Westerhof N, Helderman F, Marcus JT, Stergiopulos N, Westerhof BE, et al: RC time constant of single lung equals that of both lungs together: a study in chronic thromboembolic pulmonary hypertension. Am J Physiol Heart Circ Physiol 2009; 297:H2154–H2160.
40.
Saouti N, Westerhof N, Helderman F, Marcus JT, Boonstra A, Postmus PE, Vonk-Noordegraaf A: Right ventricular oscillatory power is a constant fraction of total power irrespective of pulmonary artery pressure. Am J Respir Crit Care Med 2010; 182: 1315–1320.
41.
MacKenzie Ross RV, Toshner MR, Soon E, Naeije R, Pepke-Zaba J: Decreased time constant of the pulmonary circulation in chronic thromboembolic pulmonary hypertension. Am J Physiol Heart Circ Physiol 2013; 305:H259–H264.
42.
Tedford RJ, Hassoun PM, Mathai SC, Girgis RE, Russell SD, Thiemann DR, et al: Pulmonary capillary wedge pressure augments right ventricular pulsatile loading. Circulation 2012; 125: 289–297.
43.
Naeije R, Manes A: The right ventricle in pulmonary arterial hypertension. Eur Respir Rev 2014; 23: 476–487.
44.
Haddad F, Doyle R, Murphy DJ, Hunt SA: Right ventricular function in cardiovascular disease, part II: pathophysiology, clinical importance, and management of right ventricular failure. Circulation 2008; 117: 1717–1731.
45.
Champion HC, Michelakis ED, Hassoun PM: Comprehensive invasive and noninvasive approach to the right ventricle-pulmonary circulation unit: state of the art and clinical and research implications. Circulation 2009; 120: 992–1007.
46.
Gaine SP, Naeije R, Peacock AJ (eds): The Right Heart. London, Springer, 2014.
47.
Campo A, Mathai SC, Le Pavec J, Zaiman AL, Hummers LK, Boyce D, et al: Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension. Am J Respir Crit Care Med 2010; 182: 252–260.
48.
Mehra MR, Park MH, Landzberg MJ, Lala A, Waxman AB; International Right Heart Failure Foundation Scientific Working Group: Right heart failure: toward a common language. J Heart Lung Transplant 2014; 33: 123–126.
49.
Sagawa K, Maughan L, Suga H, Sunagawa K (eds): Cardiac Contraction and the Pressure-Volume Relationship. Oxford, Oxford University Press, 1988.
50.
Vonk-Noordegraaf A, Westerhof N: Describing right ventricular function. Eur Respir J 2013; 41: 1419–1423.
51.
Brimioulle S, Wauthy P, Ewalenko P, Rondelet B, Vermeulen F, Kerbaul F, Naeije R: Single-beat estimation of right ventricular end-systolic pressure-volume relationship. Am J Physiol Heart Circ Physiol 2003; 284:H1625–H1630.
52.
Kuehne T, Yilmaz S, Steendijk P, Moore P, Groenink M, Saaed M, et al: Magnetic resonance imaging analysis of right ventricular pressure-volume loops: in vivo validation and clinical application in patients with pulmonary hypertension. Circulation 2004; 110: 2010–2016.
53.
Tedford RJ, Mudd JO, Girgis RE, Mathai SC, Zaiman AL, Housten-Harris T, et al: Right ventricular dysfunction in systemic sclerosis-associated pulmonary arterial hypertension. Circ Heart Fail 2013; 6: 953–963.
54.
McCabe C, White PA, Hoole SP, Axell RG, Priest AN, Gopalan D, et al: Right ventricular dysfunction in chronic thromboembolic obstruction of the pulmonary artery: a pressure-volume study using conductance catheter. J Appl Physiol (1985) 2014; 116: 355–363.
55.
Naeije R, Brimioulle S, Dewachter L: Biomechanics of the right ventricle in health and disease (2013 Grover Conference series). Pulm Circ 2014; 4: 395–406.
56.
Galiè N, Palazzini M, Manes A: Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial meta-analyses. Eur Heart J 2010; 31: 2080–2086.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.